Both LAG3 and TIM3 have been investigated as targets for inhibitory monoclonal antibodies in ovarian mice bearing ovarian cancer models and showed promising results when used in combination with other immunotherapies [27,28]. Here, LAG3 is linked to ovarian carcinoma.